• Cabaletta Bio expects registrational RESET-Myositis topline results in the second half of 2027, targeting a myositis biologics license application in first-quarter 2028.
• All six adult dermatomyositis patients maintained immunomodulator-free moderate-to-major responses through one year; 67% were steroid-free.
• Safety data from 71 patients showed 94% had no cytokine release syndrome or grade 1 events; 96% had no neurotoxicity syndrome.
• A development strategy for the preconditioning-free approach is expected in the first half of 2027.
• Operational runway extends into first-quarter 2028, covering all anticipated milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief on November 08, 2026, and is solely responsible for the information contained therein.